BMY
NYSE · Pharmaceuticals
Bristol-Myers Squibb Co
$55.00
-0.53 (-0.95%)
Financial Highlights (FY 2026)
Revenue
48.27B
Net Income
7.06B
Gross Margin
72.6%
Profit Margin
14.6%
Rev Growth
+1.5%
D/E Ratio
2.44
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 72.6% | 72.6% | 59.2% | 59.2% |
| Operating Margin | 21.5% | 19.3% | 22.1% | 21.3% |
| Profit Margin | 14.6% | 13.9% | 20.8% | 23.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 48.27B | 47.58B | 47.91B | 45.13B |
| Gross Profit | 35.05B | 34.55B | 28.35B | 26.71B |
| Operating Income | 10.38B | 9.21B | 10.61B | 9.60B |
| Net Income | 7.06B | 6.27B | 9.95B | 10.61B |
| Gross Margin | 72.6% | 72.6% | 59.2% | 59.2% |
| Operating Margin | 21.5% | 19.3% | 22.1% | 21.3% |
| Profit Margin | 14.6% | 13.9% | 20.8% | 23.5% |
| Rev Growth | +1.5% | +1.5% | +15.6% | -1.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 39.12B | 39.12B | 44.69B | 49.22B |
| Total Equity | 16.02B | 16.02B | 47.12B | 45.92B |
| D/E Ratio | 2.44 | 2.44 | 0.95 | 1.07 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 13.70B | 12.83B | 15.42B | 13.24B |
| Free Cash Flow | — | — | 6.08B | 6.45B |